Holen Sie sich die Stockscreener-App
790.38
0.47%
3.07
Schlusskurs vom Vortag:
$787.31
Offen:
$787.08
24-Stunden-Volumen:
217.33K
Relative Volume:
0.65
Marktkapitalisierung:
$49.07B
Einnahmen:
$4.16B
Nettoeinkommen (Verlust:
$1.29B
KGV:
40.36
EPS:
19.5837
Netto-Cashflow:
$734.26M
1W Leistung:
+0.96%
1M Leistung:
+0.76%
6M Leistung:
-7.45%
1J Leistung:
+38.99%
1-Tages-Spanne:
$778.13
$792.00
1-Wochen-Bereich:
$777.14
$840.67
52-Wochen-Spanne:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
789.10 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
428.05 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
715.85 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.62 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
314.47 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-12-18 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Fortgesetzt | Truist | Buy |
| 2025-09-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
| 2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-06-15 | Eingeleitet | Societe Generale | Sell |
| 2023-05-31 | Eingeleitet | UBS | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Eingeleitet | William Blair | Outperform |
| 2022-10-12 | Eingeleitet | Oppenheimer | Perform |
| 2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Fortgesetzt | Stifel | Buy |
| 2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-18 | Eingeleitet | UBS | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Eingeleitet | Redburn | Neutral |
| 2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-09-16 | Fortgesetzt | Cowen | Outperform |
| 2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-18 | Fortgesetzt | SunTrust | Buy |
| 2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-12-17 | Eingeleitet | Goldman | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-06-29 | Eingeleitet | Nomura | Buy |
| 2018-04-09 | Eingeleitet | SunTrust | Buy |
| 2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
RBC Capital maintains argenx stock price target at $890 on uptake potential - Investing.com
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 By Investing.com - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 - Investing.com
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com South Africa
argenx posts 63% revenue growth on strong Vyvgart sales By Investing.com - Investing.com South Africa
argenx appoints Karen Massey as CEO, founder moves to chair - Investing.com
argenx to Present at BofA Securities 2026 Health Care Conference - ChartMill
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer - ChartMill
ARGX.BR Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SE (EBR:ARGX) - ChartMill
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 - ChartMill
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN) - The Globe and Mail
argenx SE Stock Baskets | MEX:ARGXN - GuruFocus
argenx SE Stock Operating Data - GuruFocus
argenx SE (MEX:ARGXN) Stock News, Headlines & Updates - GuruFocus
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Argenx SE stock (NL0010832176): Is its rare disease focus strong enough to unlock sustained U.S. gro - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's momentum strong enough to unlock new upside? - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's expansion strong enough to unlock new upside? - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's rare disease dominance strong enough to unlock new upsi - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. momentum strong enough to unlock new upside? - AD HOC NEWS
argenx SE (MEX:ARGXN) Competitors 2026 - GuruFocus
Who's Buying or Selling argenx SE (MEX:ARGXN) Stock Today? - GuruFocus
argenx SE (MEX:ARGXN) Stock Price, Trades & News - GuruFocus
argenx SE (MEX:ARGXN)Valuation Measures & Financial Statistics - GuruFocus
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Avalo Therapeutics (AVTX) - The Globe and Mail
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. expansion strong enough to unlock new upside? - AD HOC NEWS
Argenx shares see TD Cowen reiterate Buy on Vyvgart strength By Investing.com - Investing.com South Africa
Argenx shares see TD Cowen reiterate Buy on Vyvgart strength - Investing.com
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. dominance now the key growth lever? - AD HOC NEWS
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026 By Investing.com - Investing.com South Africa
Argenx Leads Turnover Charts with $250 Million in Trades, Concealing a Slight Decline During Sector Shifts - Bitget
How is argenx (ARGX) Stock performing in 2026 | ARGX Q4 Earnings: Beats Estimates by $1.77Share Dilution - Newser
ARGX Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP - GlobeNewswire Inc.
Stocks Showing Improved Relative Strength: argenx ADR - Investor's Business Daily
Target Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx SE Stock: Biotech Leader in Autoimmune Therapies Driving Investor Interest with Strong Growth - AD HOC NEWS
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Is Viridian Therapeutics Stock Falling Monday? - Sahm
argenx SE (HAM:1AEA) Stock Price, Trades & News - GuruFocus
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Stock Faces Pressure Amid Pipeline Setbacks and Market Volatility in Biotech Sector - ad-hoc-news.de
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Form 6K argenx NV ADR For: 20 March By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 20 March - Investing.com
argenx announces Annual General Meeting of Shareholders on May 6, 2026 - ChartMill
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Argenx SE stock faces pressure as Iron Triangle Partners trims position amid biotech sector watchlis - AD HOC NEWS
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):